JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on October 8, 2003; DOI: 10.1124/jpet.103.054346


0022-3565/03/3073-987-994$20.00
JPET 307:987-994, 2003
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.103.054346v1
307/3/987    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hamaguchi, E.
Right arrow Articles by Nagai, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hamaguchi, E.
Right arrow Articles by Nagai, Y.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*12-O-TETRADECANOYLPHORBOL-13-ACETATE

CELLULAR AND MOLECULAR

Tumor Necrosis Factor-{alpha} and Troglitazone Regulate Plasminogen Activator Inhibitor Type 1 Production through Extracellular Signal-Regulated Kinase- and Nuclear Factor-{kappa}B-Dependent Pathways in Cultured Human Umbilical Vein Endothelial Cells

Erika Hamaguchi, Toshinari Takamura, Akiko Shimizu, and Yukihiro Nagai

Department of Endocrinology and Metabolism, Kanazawa University Graduate School of Medical Science, Ishikawa, Japan

Plasminogen activator inhibitor type 1 (PAI-1) plays a role in the development of atherosclerosis in diabetic patients. PAI-1 is produced by endothelial cells stimulated with various inflammatory cytokines, such as tumor necrosis factor (TNF)-{alpha}, which induces insulin resistance. In diabetic patients, troglitazone, a thiazolidinedione, can lower the concentration of PAI-1. We investigated the TNF-{alpha}-induced signaling pathway that leads to PAI-1 synthesis and the target step of troglitazone in this pathway. TNF-{alpha} induced PAI-1 mRNA expression and protein production in human umbilical vein endothelial cells (HUVECs). A specific inhibitor for p38 mitogen-activated protein kinase, 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole (SB 203580), and a protein kinase C inhibitor, calphostin C, had no inhibitory effects on TNF-{alpha}-induced PAI-1 secretion. A protein tyrosine kinase inhibitor, genistein, completely inhibited TNF-{alpha}-induced PAI-1 secretion, whereas an inhibitor of extracellular signal-regulated kinase (ERK) kinase, 2'-amino-3'-methoxyflavone (PD98059), and a nuclear factor-{kappa}B (NF-{kappa}B) inhibitor, emodin, partly inhibited TNF-{alpha}-induced PAI-1 secretion. Together, PD98059 and emodin completely inhibited TNF-{alpha}-induced PAI-1 secretion, suggesting that both NF-{kappa}B-dependent and NF-{kappa}B-independent pathways are involved in TNF-{alpha}-induced signal pathway to PAI-1 production and that the latter pathway is mediated by activation of ERK. Furthermore, we have shown that troglitazone inhibited both TNF-{alpha}-induced PAI-1 protein secretion and mRNA in HUVECs. Genistein, but neither PD98059 nor emodin, was additive to the inhibitory effect of troglitazone on TNF-{alpha}-induced PAI-1 secretion. These results indicate That ERK and NF-{kappa}B are possible targets of TNF-{alpha} and troglitazone in the regulation of PAI-1 production.


Received for publication May 12, 2003
Accepted August 14, 2003.

Address correspondence to: Dr. Toshinari Takamura, Department of Endocrinology and Metabolism, Kanazawa University Graduate School of Medical Science, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8641, Japan. E-mail: tt{at}medf.m.kanazawa-u.ac.jp




This article has been cited by other articles:


Home page
Am. J. Respir. Cell Mol. Bio.Home page
C.-L. Chung, J.-R. Sheu, H.-E. Liu, S.-C. Chang, Y.-C. Chou, W.-L. Chen, D.-S. Chou, and G. Hsiao
Dynasore, a Dynamin Inhibitor, Induces PAI-1 Expression in MeT-5A Human Pleural Mesothelial Cells
Am. J. Respir. Cell Mol. Biol., June 1, 2009; 40(6): 692 - 700.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
J. I. Beier, L. Guo, C. von Montfort, J. P. Kaiser, S. Joshi-Barve, and G. E. Arteel
New Role of Resistin in Lipopolysaccharide-Induced Liver Damage in Mice
J. Pharmacol. Exp. Ther., June 1, 2008; 325(3): 801 - 808.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
C. E. Hafer-Macko, F. M. Ivey, J. D. Sorkin, and R. F. Macko
Microvascular tissue plasminogen activator is reduced in diabetic neuropathy
Neurology, July 17, 2007; 69(3): 268 - 274.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Mukai, C.-Y. Wang, Y. Rikitake, and J. K. Liao
Phosphatidylinositol 3-kinase/protein kinase Akt negatively regulates plasminogen activator inhibitor type 1 expression in vascular endothelial cells
Am J Physiol Heart Circ Physiol, April 1, 2007; 292(4): H1937 - H1942.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. H. Sohn, C. B. Deming, D. C. Johns, H. C. Champion, C. Bian, K. Gardner, and J. J. Rade
Regulation of endothelial thrombomodulin expression by inflammatory cytokines is mediated by activation of nuclear factor-kappa B
Blood, May 15, 2005; 105(10): 3910 - 3917.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
J. P. Luyendyk, W. B. Mattes, L. D. Burgoon, T. R. Zacharewski, J. F. Maddox, G. N. Cosma, P. E. Ganey, and R. A. Roth
Gene Expression Analysis Points to Hemostasis in Livers of Rats Cotreated with Lipopolysaccharide and Ranitidine
Toxicol. Sci., July 1, 2004; 80(1): 203 - 213.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.